HTG Molecular Diagnostics is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based Tucson, Arizona.
Current Team (11)Update
Vice President, Chief Legal Counsel
President and CEO
SVP Commercial Operations
Vice President of Finance, Administration and CFO
Vice President of Translational Science and Chief Medical Officer
Funding Rounds (5) - $47.2MUpdate
Board Members and Advisors (9)Update
Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation.
Venture Capital Firm
Merck Capital Ventures invests in companies in various stages of development from the first round...
Solstice Capital seeks superior venture capital returns for its limited partners through...
3430 E. Global Loop
Tucson, AZ 85706